Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The round was led by investors including Yuanhenglizhen Management, Cornerstone Capital, Salubris Pharma, Nanshan SEI Investment, Beihang Investment, New Alliance Capital, and GL Ventures. The proceeds will be used for product research and development, clinical trials, commercialization, and the construction of a novel active plant intervention platform.
Company Background and Product Portfolio
Founded in 2016, Core Medtech is known for its innovative solutions in heart failure treatment. The company boasts a new generation of its subminiature magnetic suspension artificial heart and new-generation implantable artificial heart products. These advancements highlight Core Medtech’s commitment to improving patient outcomes through cutting-edge technology.
Future Prospects and Strategic Use of Funds
The Series C financing round positions Core Medtech to further enhance its product offerings and expand its market reach. By investing in research and development, clinical trials, and commercialization efforts, Core Medtech aims to solidify its position as a leader in the field of heart failure mechanical circulatory support. The construction of a novel active plant intervention platform also underscores the company’s dedication to innovation and sustainable development.-Fineline Info & Tech
